Anticancer Agents from Unique Natural Products Sources

References

• Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel R (1995): PD-098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489–27494.
   PubMed Web of Science ®Google Scholar
• Alessi DR, Cohen P, Ashworth A, Cowley S, Leevers SJ, Marshall CJ (1995): Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol 255: 279–290.
   PubMed Web of Science ®Google Scholar
• Altmann KH (2003): Epothilone B and its analogs — a new family of anticancer agents. Mini Rev Med Chem 3: 149–158.
   PubMed Web of Science ®Google Scholar
• Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990): Basic local alignment search tool. J Mol Bio 215: 403–410.
   PubMed Web of Science ®Google Scholar
• An K-D, Nishida H, Miura Y, Yokota A (2003): Molecular evo-lution of adenylating domain of aminoadipate reductase. BMC Evol Biol 3: 9–15 (http://www.biomedcentral.com/ 1471-2148/3/9).
   Google Scholar
• Anderson HJ, Coleman JE, Andersen RJ, Roberge M (1997): Cytotoxic peptides hemiasterlin, hemiasterlin A, and hemi-asterlin B induce mitotic arrest and abnormal spindle for-mation. Cancer Chemother Pharmacol 39: 223–226.
   Google Scholar
• Andersen RJ, Coleman JE, Piers E, Wallace DJ (1997): Total synthesis of (—)-hemiasterlin, a structurally novel tripeptide that exhibits potent cytotoxic activity. Tetrahedron Lett 38: 317–320.
   Web of Science ®Google Scholar
• Andersen RJ, Piers E, Nieman J, Coleman J, Roberge M (1999): WO Patent 99/3250.
   Google Scholar
• Angeles TS, Steffler C, Bartlett BA, Hudkins RL, Stephens RM, Kaplan DR, Dionne CA (1996): Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity. Anal Biochem 236: 49–55.
   PubMed Web of Science ®Google Scholar
• Bai R, Durso NA, Sackett DL, Hamel, E (1999): Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 38: 14302–14310.
   PubMed Web of Science ®Google Scholar
• Barbacid M (1987): RAS Genes. Ann Rev Biochem 56: 779–822.
   PubMed Web of Science ®Google Scholar
• Boyd, MR (1989): Status of the NCI preclinical drug discovery screen. In: Principles and Practices of Oncology 3, pp. 1–10, J.B. Lippincott Publish.
   Google Scholar
• Coleman JE, de Silva ED, Kong F, Andersen RJ, Allen TM (1995): Cytotoxic peptides from the marine sponge Cym-bastela sp. Tetrahedron 51: 10653–10662.
   Web of Science ®Google Scholar
• Coleman JE, Patrick BO, Andersen RJ, Rettig SJ (1996): Hemiasterlin methyl ester. Acta Cryst C52: 1525–1527.
   Google Scholar
• Crews P, Farias JJ, Emrich R, Keifer PA (1994): Milnamide A, an unusual cytotoxic tripeptide from the marine sponge Auletta cf. constricta J Org Chem 59: 2932–2934.
   Web of Science ®Google Scholar
• Curman D, Cinel B, Williams DE, Rundle N, Block WD, Goodarzi AA, Hutchins JR, Clarke PR, Zhou B-B, Lees-Miller SP, Andersen RJ, Roberge M (2001): Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk 1 and Chk2 by the marine sponge alkaloid debromo-hymenialdisine. J Biol Chem 276: 17914–17919.
   Google Scholar
• de Silva ED, Andersen RJ, Allen TM (1990): Geodiamolide C to Geodiamolide F, new cytotoxic cyclodepsipeptides from the marine sponge Pseudaxinyssa sp. Tetrahedron Lett 31: 489–492.
   Web of Science ®Google Scholar
• Discafani CM, Carroll ML, Floyd Jr MBF, Hollander IJ, Husain Z, Johnson BD, Kitchen D, May MK, Malo MS, Mirmick Jr AA, Nilakantan R, Shen R, Wang Y-F, Wissner A, Greenberger LM (1999): Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[443-bromophenypamino]-6-quirtaxoliny1]-2-buty-namide (CL-387,785). Biochem Pharmacol 57: 917–925.
   Google Scholar
• Downing, KH (2000): Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 16: 89–111.
   PubMed Web of Science ®Google Scholar
• Dumontet C (2000): Mechanism of action and resistance to tubulin-binding agents. Exp Opin Invest Drugs 9: 779–788.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Flanders TY, Pollock PM, Hayward NK, (1997): The CDKN2A (p16) gene and human cancer. Mol Med 3: 5–20.
   PubMed Web of Science ®Google Scholar
• Gamble WR, Durso NA, Fuller RW, Westergaard CK, Johnson TR, Sackett DL, Hamel E, Cardellina JH, Boyd MR (1999): Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina sponges. Bioorg Med Chem 7: 1611–1615.
   Google Scholar
• Gibbons JJ, Discafani C, Peterson R, Hernandez R, Skotnicki J, Frost P (1999): The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Proc Am Assoc Cancer Res 40: 301.
   Google Scholar
• Gibbs (2000): Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest 105: 9–13.
   PubMed Web of Science ®Google Scholar
• Gottesman MM (2002): Mechanisms of cancer drug resistance. Annu Rev Med 53: 615–627.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE (2002): Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48–58.
   PubMed Web of Science ®Google Scholar
• Hall M, Peters G (1996): Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68: 67–108.
   PubMed Web of Science ®Google Scholar
• Hamel E (1996): Antimitotic natural products and their interac-tions with tubulin. Med Res Rev 16: 207–231.
   PubMed Web of Science ®Google Scholar
• Hamel E, Covell DG (2002): Antimitotic peptides and dep-sipeptides. Curr Med Chem Anti-Canc Agents 2: 19–53.
   PubMedGoogle Scholar
• Hanks SK, Hunter T (1995): The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classi-fication. FASEB 9: 576–596.
   PubMed Web of Science ®Google Scholar
• He H, Ding W-D, Bernan VS, Richardson AD, Ireland CM, Greenstein M, Ellestad GA, Carter GT (2001): Lomaiviticins A and B, potent antitumor antibiotics from Micromonospora lomaivitiensis. J Am Chem Soc 123: 5362–5363.
   PubMed Web of Science ®Google Scholar
• Hirama T, Koeffier HP (1995): Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86: 841–854.
   PubMed Web of Science ®Google Scholar
• Hunter T (1997): Oncoprotein networks. Cell 88: 333–346.
   PubMed Web of Science ®Google Scholar
• Imamura N, Nishijima M, Takadera T, Adachi K, Sakai M, Sano H (1997): New anticancer antibiotics pelagiomicins, pro-duced by a new marine bacterium Pelagiobacter variabilis. J Antibiot 50: 8–12.
   PubMed Web of Science ®Google Scholar
• Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skolnick MH (1994): A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436–440.
   PubMed Web of Science ®Google Scholar
• Kaplan JA, Nunes M, Ayral-Kaloustian S, Krishriamurthy G, Loganzo F, Greenberger LM, Minnick A, May M, Zask A (2002): Hemiasterlin photoaffinity ligands: [31-1] benzophe-none analogs of HTI-286. National Medicinal Chemistry Symposium: abstract 49.
   Google Scholar
• Kfir R, Johannsen E, Vleggaar R (1986): Mutagenic activity of austocystins-secondary metabolities of Aspergillus ustus. Bull Environ Contam Toxicol 37: 643–650.
   PubMed Web of Science ®Google Scholar
• Kolch W (2000): Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J351: 289–305.
   PubMed Web of Science ®Google Scholar
• Kramer RA, Zakher J, Kim G (1988): Role of glutathione redox cycle in acquired and de novo multidrug resistance. Science 241: 694–698.
   PubMed Web of Science ®Google Scholar
• Kramer RA, Weber TK, Morse B (1993): Constitutive expres-sion of multidrug resistance in human colorectal tumors and cell lines. Br J Cancer 67: 959–968.
   PubMed Web of Science ®Google Scholar
• Lackey K, Cory M, Davis R, Frye SV, Harris PA, Hunter RN, Jung DK, McDonald OB, McNutt RW, Peel MR, Rutkowske RD, Veal JM, Wood ER (2000): The discovery of potent cRaf-1 kinase inhibitors. Bioorg Med Chem Lett 10: 223–226.
   PubMed Web of Science ®Google Scholar
• Lavoie JN, liAllemain G, Brunet A, Muller R, Pouyssegur J (1996): Cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271: 20608–20616.
   PubMed Web of Science ®Google Scholar
• Lee T, Yun S-H, Hodge KT, Humber RA, Krasnoff SB, Turgeon GB, Yoder OC, Gibson DM (2001): Polyketide synthase genes in insect- and nematode-associated fungi. Appl Microbiol Biotechnol 56: 181–187.
   PubMed Web of Science ®Google Scholar
• Lerner EC, Zhang TT, Knowles DB, QianY, Hamilton AD, Sebti M (1997): Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylger-anyltransferase I inhibitor in human tumor cell lines. Onco-gene 15: 1283–1288.
   Google Scholar
• Levitzki A, Gazit A (1995): Tyrosine kinase inhibition: an approach to drug development Science 267: 1782–1788.
   Google Scholar
• Lewis TS, Shapiro PS, Ahn NG (1998): Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49–139.
   PubMed Web of Science ®Google Scholar
• Loganzo F, Annable T, Xingzhi T, Morilla DB, Hari M, Musto S, Zask A, Kaplan J, Poruchynsky M, Fojo TMGL (2003): Cells resistant to HTI-286 do not over-express P-glycopro-tein but have low drug accumulation and a point mutation in a-tubulin. Proc Amer Assoc Cancer Res 44: 1307 (2nd ed.).
   Google Scholar
• Loganzo F, Discafani C, Annable T, Beyer C, Musto S, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM (2003): HTI-286, a synthetic analogue of the tripep-tide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 63: 1838–1845.
   Google Scholar
• Mallon R, Feldberg LR, Kim SC, Collins K, Wojciechowicz D, Hollander I, Kovacs ED, Kohler C (2001): An enzyme-linked immunosorbent assay for the Raf/MEK-1/MAPK signaling cascade. Anal Biochem 294: 48–54.
   PubMed Web of Science ®Google Scholar
• Martin JF (1998): New aspects of genes and enzymes for 13-lactam antibiotic biosynthesis Appl. Microbiol Biotechnol 50: 1–15.
   PubMed Web of Science ®Google Scholar
• McDonald LA, Capson TL, Krishriamurthy G, Ding W, Ellestad GA, Bernan VS, Maiese WM, Lassota P, Discafani C, Kramer RA, Ireland CM (1996): Namenamicin, a new enediyne antitumor antibiotic from the marine ascidian Polysyncraton lithostrotum. J Amer Chem Soc 118: 10898–10899.
   Web of Science ®Google Scholar
• McDonald OB, Chen WJ, Ellis B, Hoffman C, Overton L, Rink M, Smith A, Marshall CJ, Wood ER (1999): A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. Anal Biochem 268: 318–329.
   PubMed Web of Science ®Google Scholar
• Meijer L, Kim S-H (1997): Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol 283: 113–128.
   PubMed Web of Science ®Google Scholar
• Meijer L, Thunnissen A-MWH, White AW, Gamier M, Nikolic M, Tsai L-H, Walter J, Cleverley KE, Salinas PC, Wu Y-Z, Biemat J, Mandelkow E-M, Kim S-H, Pettit GR (2000): Inhibition of cyclin-dependent kinases, GSK-3 and CK1, by hymenialdisine, a marine sponge constituent. Chem Biol 7: 51–63.
   PubMed Web of Science ®Google Scholar
• Mithani S, Weeratunga G, Taylor NJ, Dmitrienko GI (1994): The kinamycins are diazofluorenes and not cyanocarbazoles. J Amer Chem Soc 116: 2209–2210.
   Web of Science ®Google Scholar
• Morgan DO (1995): Principles of CDK regulation. Nature 374: 131–134.
   PubMed Web of Science ®Google Scholar
• Monks A, Scudiero D, Skehan P (1991): Feasibility of a high-flux anticancer drug screen using a diverse panel of cul-tured human tumor cell lines. J Natl Cancer Inst 83: 757–766.
   PubMed Web of Science ®Google Scholar
• Nieman J, Coleman J, Wallace D, Piers E, Lim LY, Roberge M, Andersen RJ (2003): synthesis and antimitotic/cytotoxic activity of hemiasterlin analogs. J Nat Prod 66: 183–199.
   PubMed Web of Science ®Google Scholar
• Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994): Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753–756.
   PubMed Web of Science ®Google Scholar
• Nogales E, Whittaker M, Milligan RA, Downing KH (1999): High-resolution model of the microtubule. Cell 96: 79–88.
   PubMed Web of Science ®Google Scholar
• Nunes M, Kaplan J, Loganzo F, Zask A, Ayral-Kaloustian S, Greenberger L (2002): Two photoaffinity analogs of HTI-286, a synthetic analog of hemiasterlin, interact with alpha-tubulin. Eur J Cancer 38: S119.
   Google Scholar
• O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Don FA, Yao KS (1999): c-Raf-1 depletion and tumor responses in patients treated with the c-Raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res 5: 3977–3982.
   PubMed Web of Science ®Google Scholar
• Pang L, Sawada T, Decker SJ, Saltiel AR (1995): Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 23: 13585–13588.
   Google Scholar
• Pawson T, Saxton TM (1999): Signaling networks - do all roads lead to the same genes? Cell 97: 675–678.
   Google Scholar
• Poruchynsky MS, Kim JH, Nogales E, Loganzo F, Greenberger LM (2003): Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analog, HTI-286, have mutations in a- or 0-tubulin and increased microtubule stability. Proc Am Assoc Cancer Res 44: 535 (2nd ed.).
   Google Scholar
• Ratain MJ, Undevia S, Janisch L, Roman S, Mayer P, Buckwalter M, Foss D, Hamilton BL, Fischer J, Bukowski RM (2003): Phase land pharmacological study of HTI-286, a novel antimicrotubule agent: correlation of neutropenia with time above threshold plasma concentration. Proc Am Soc Clin Oncol: abstract 516.
   Google Scholar
• Roberge M, Cinel B, Anderson HJ, Lim L, Jiang X, Xu L, Kelly MT, Andersen RJ (2000): Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleuther-obin, and paclitaxel in natural extracts. Cancer Res 60: 5052–5058.
   PubMed Web of Science ®Google Scholar
• Robinson MJ, Cobb MH (1997): Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180–186.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Tolcher AW (2001): Antimicrotubule Agents. In: Devita Jr VT, Hellman S, Rosenberg SA, eds., Cancer Principles and Practice. 6th ed., Philadelphia, Lippincott Williams and Wilkins, pp. 431–452.
   Google Scholar
• Salomon DS, Brandt R, Ciadiello F, Normanno N (1995): Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haema-tol 19: 183–232.
   Google Scholar
• Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, WilandA, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR (1999): Block-ade of the MAP kinase pathway supresses growth of colon tumors in vivo. Nat Med 5: 810–816.
   PubMed Web of Science ®Google Scholar
• Stehelin D; Varmus HE, Bishop JM, Vogt PK (1976): DNA related to the transforming gene of avian sarcoma virus is present in normal avian DNA. Nature 260: 170–173.
   PubMed Web of Science ®Google Scholar
• Steyn PS, Vleggaar R (1974): Austocystins. Six novel dihydro-furol[3',2' : 4,5]furo[3,2-b]xanthenones from Aspergillus ustus. J Chem Soc Perkin I 19: 2250–2256.
   Google Scholar
• Steyn PS, Vleggaar R (1975): Dihydrofuro[3',2' : 4,5]furo[3,2-b]xanthenones: the structures of austocystins G, H, and I. J South African Chemical Institute 28: 375–377.
   Google Scholar
• Strawn, LM, Shawver LK (1998): Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp Opin Invest Drugs 7: 553–573.
   PubMedGoogle Scholar
• Talpir R, Benayahu Y, Kashman Y, Pannell L, Schleyer M (1994): Hemiasterlin and geodiamolide-TA - 2 new cyto-toxic peptides from the marine sponge Hemiasterella minor (Kirkpatrick). Tetrahedron Lett 35: 4453–4456.
   Google Scholar
• Tasdemir D, Mallon R, Greenstein M, Feldberg LR, Kim SC, Collins K, Wojciechowicz W, Mangalindan GC, Concepción GP, Harper MK, Ireland CM (2002): Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1) J Med Chem 45: 529–532.
   Google Scholar
• UN. Convention on Biological Diversity, June 2, 1992, UN. Doc. DPI/130/7.
   Google Scholar
• Weber G, Schorgendorfer K, Schneider-Scherzer E, Leitner E (1994): The peptide synthetase catalyzing cyclosporine production in Tolypocladium niveum is encoded by a giant 45.8-kilobase open reading frame. Curr Genet 26: 120–125.
   Google Scholar
• Weinber RA (1991): Molecular Biology of Carcinogenesis. In: Broder S, ed., Molecular Foundations of Oncology. Williams & Wilkins, pp. 27-39.
   Google Scholar
• Woodburn JR (1999): The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241–250.
   PubMed Web of Science ®Google Scholar
• Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, Sausville EA (1999): Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res 59: 2566–2569.
   PubMed Web of Science ®Google Scholar
• Zask A, Birnberg G, Cheung K, Cole D, Kaplan J, Niu C, Norton E, Sandanayaka V, Suayan R, Tang Z, Yamashita A, Loganzo F, Beyer C, Discafani C, Greenberger LM, Ayral-Kaloustian S (2002): Synthesis and biological activity of analogs of the antimicrotubule agent HTI-286. Proc Amer Assoc Cancer Res 43: 737.
   Google Scholar